Aleniglipron for Liver Disease

This trial aims to understand how the drug aleniglipron works in people with liver problems. Researchers seek to determine the best dose for these patients by studying how the body processes the drug. Participants will take aleniglipron orally, and the trial will consist of two parts testing this method. It suits adults with liver issues who understand the trial process and can follow instructions. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that aleniglipron is generally safe, based on data from over 625 people in various studies. Notably, no reports have indicated liver damage caused by the drug, which is crucial since the current trial focuses on liver disease. Although some participants stopped taking the treatment due to side effects, this accounted for only about 10.4% of participants. Overall, aleniglipron is usually well-tolerated and as safe as similar treatments.¹²³⁴⁵

Unlike the usual treatments for liver disease, which often focus on managing symptoms or slowing disease progression, Aleniglipron brings something new to the table. Researchers are excited about Aleniglipron because it is designed to be administered orally, which could improve patient convenience and adherence compared to more invasive treatments like injections. The drug works through a novel mechanism that directly targets pathways in the liver, potentially offering more effective and direct treatment of the disease itself. This innovative approach could provide significant advantages over current options, making it an exciting development in the field.

Research has shown that aleniglipron, a pill that activates certain receptors in the body, yields promising results for weight loss. Participants lost up to 16.3% of their weight compared to those taking a placebo. On average, individuals lost between 13.6% and 15.3% of their weight over 44 weeks. Importantly, studies reported no serious liver problems, suggesting it is likely safe for the liver. While aleniglipron is primarily known for aiding weight loss, it might also improve liver health by reducing fat and inflammation. Participants in this trial will receive aleniglipron orally to evaluate its effects on liver disease.⁶⁷⁸⁹¹⁰